Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.07
Price-13.22%
-$0.62
1Y
Price
Market Cap
$1.817b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-125.5%
EBITDA Margin-135.3%
Net Profit Margin-132.7%
Free Cash Flow Margin-125.5%
EBITDA Margin-135.3%
Net Profit Margin-132.7%
Free Cash Flow MarginRevenue
$285.608m
+52.6%
1y CAGR+4583.9%
3y CAGR+3437.9%
5y CAGREarnings
-$353.860m
-6.8%
1y CAGR-0.9%
3y CAGR-4.6%
5y CAGREPS
-$0.92
+6.3%
1y CAGR+20.9%
3y CAGR+12.7%
5y CAGRBook Value
$721.754m
$925.665m
Assets$203.911m
Liabilities$47.776m
DebtDebt to Assets
5.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$305.021m
+3.4%
1y CAGR-4.7%
3y CAGR-8.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company